Amylin: A Novel Diabetes and Obesity Therapy

https://www.medscape.com/viewarticle/amylin-novel-diabetes-and-obesity-therapy-2026a1000lvm?ecd=WNL_trdalrt_pos1_ous_260707_etid8484935&uac=148436CN&impID=8484935 For several years now, SGLT2 inhibitors and incretin therapies have dominated the diabetes therapeutic landscape because of their glucose-lowering potency, low associated risk for hypoglycemia, weight-loss properties, and other cardio-renal-metabolic benefits. Incretin therapies are also well established as an obesity treatment in patients without diabetes.